Literature DB >> 10962219

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response.

S J Tsai1, C J Hong, Y W Yu, C H Lin, H L Song, H C Lai, K H Yang.   

Abstract

Serotonin is implicated in the pathogenesis of schizophrenia. Following serotonin release, the serotonin transporter (5-HTT) is the major determinant of serotonin inactivation. The present study tested the hypothesis that a biallelic polymorphism in the 5' regulatory region of the 5-HTT gene (5-HTTLPR) confers susceptibility to schizophrenia, association with the clinical manifestations of schizophrenia or clozapine response. 90 treatment-resistant schizophrenic patients were assessed using the Brief Psychiatric Rating Scale before and after clozapine treatment. The results demonstrated that the 5-HTTLPR variants did not play a major role in the susceptibility, clinical manifestations or clozapine response in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962219     DOI: 10.1016/s0920-9964(99)00170-x

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

Review 1.  Treatment-refractory schizophrenia.

Authors:  P F Buckley; L D Wiggins; S Sebastian; B Singer
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

3.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

Review 4.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 5.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

6.  Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia.

Authors:  C-U Pae; A Serretti; P Artioli; T-S Kim; J-J Kim; C-U Lee; S-J Lee; I-H Paik; C Lee
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

Review 7.  Genetic predictors of therapeutic response to clozapine: current status of research.

Authors:  Dalu Mancama; Maria J Arranz; Robert W Kerwin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.

Authors:  Charles U Nnadi; Anil K Malhotra
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

Review 9.  Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain.

Authors:  Anil K Malhotra
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia.

Authors:  Tea Terzić; Matej Kastelic; Vita Dolžan; Blanka Kores Plesničar
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.